COTI-219 is a unique and potentially impactful compound in several common cancers including non-small cell and small cell lung cancer, colon cancer and other cancers with RAS mutations. RAS mutations are found in more than 30% of human cancers. The presumed mechanism of action of COTI-219 is undergoing final validation studies but it is clearly different from that of COTI-2.
Acute Myelogenous Leukemia (AML), is the most common type of acute leukemia in older patients with about 18,500 new cases and 9,000 deaths annually in the U.S. alone. Unfortunately five-year survival rates remain poor. Our drug discovery project has targeted multiple kinases (enzymes) that are abnormal in AML. We have identified multiple scaffolds and optimized several drug candidates on each scaffold. Early preclinical results are promising
Our pipeline also includes several other lead programs including MRSA, MS and Alzheimer’s disease. While we are excited about the future of our robust pipeline, at this time we remain strategically focused of advancing COTI-2 through the clinical trial process with our partners at MD Anderson and Northwestern University.